FRONTIER 1
About the trial
This study is investigating how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medication that will be used for prevention of bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected with a thin needle in the skin of the stomach, using a pen-injector.
275 participants are currently enroled in the trial
How DCR - CIU supports the trial
DCR - CIU was involved in multiple aspects of the trial conduct: the planning, coordination and conduct of the study visits; collection, processing, storage and shipping of biological samples, subcutaneous IMP administration and accountability, maintenance of the Investigator Site File, and data entry
Principal Investigator
Prof. Dr. med. Johanna Anna Kremer Hovinga, Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor
Sponsor
Novo Nordisk A/S